<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Peptide Science Desk</title><description>US peptide regulation, trials and evidence</description><link>https://peptidesciencedesk.com/</link><item><title>Compounded vs. FDA-Approved Peptides: What the Difference Means</title><link>https://peptidesciencedesk.com/articles/compounded-vs-fda-approved-peptides.html</link><guid isPermaLink="true">https://peptidesciencedesk.com/articles/compounded-vs-fda-approved-peptides.html</guid><description>What FDA says about compounded drugs versus FDA-approved drugs, 503A pharmacies vs 503B outsourcing facilities, and buying compounded drugs online.</description><pubDate>Fri, 16 Oct 2026 00:00:00 GMT</pubDate></item><item><title>FDA&apos;s 503A Bulks List and Interim Categories Explained, and Where BPC-157 Stands in 2026</title><link>https://peptidesciencedesk.com/articles/fda-503a-bulks-categories-bpc-157-2026.html</link><guid isPermaLink="true">https://peptidesciencedesk.com/articles/fda-503a-bulks-categories-bpc-157-2026.html</guid><description>A source-linked explainer on how FDA&apos;s 503A bulks list and interim categories 1-3 work, and FDA&apos;s July 2026 PCAC proposal on BPC-157.</description><pubDate>Fri, 16 Oct 2026 00:00:00 GMT</pubDate></item></channel></rss>